Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio Inc.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its primary endpoint
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS).
60 Degrees Pharmaceuticals Inc's (NASDAQ: SXTP) subsidiary, 60P Australia Pty Ltd, has withdrawn its investigational new drug (IND) application for ACLR8-LR, a Phase 2B study of the use of tafenoquine